Francine at 13:23, 15 December 2025

2025-12-15T13:23:23Z

← Older revision		Revision as of 13:23, 15 December 2025
Line 4:		Line 4:
	<span style="display:none">latviacountry</span>		<span style="display:none">latviacountry</span>
	Go back to [[Riga Eastern Clinical University Hospital]] page		Go back to [[Riga Eastern Clinical University Hospital]] page

			=== Trials: How to participate ===
			'''Contact information:''' [https://aslimnica.lv/profesionaliem/zinatne/zalu-izpetes-kliniskie-petijumi/ Click here to access].


	'''NCTID''': NCT01903733		'''NCTID''': NCT01903733
Line 206:		Line 210:
	<span style="display:none">hasCancerType::D37-D48: Growths of uncertain nature</span>		<span style="display:none">hasCancerType::D37-D48: Growths of uncertain nature</span>
	<span style="display:none">hasCancerType::unknown</span>		<span style="display:none">hasCancerType::unknown</span>
			<span style="display:none">isTrial</span>

Lucas: Update categories.

2025-12-06T12:42:16Z

Update categories.

← Older revision		Revision as of 12:42, 6 December 2025
Line 185:		Line 185:
	'''Recruitment Status''': TERMINATED		'''Recruitment Status''': TERMINATED
	'''Condition''': Small Cell Lung Cancer		'''Condition''': Small Cell Lung Cancer
			<span style="display:none">hasCancerType::C00-D48: All neoplasms</span>
			<span style="display:none">hasCancerType::C00-C97: All cancer types</span>
			<span style="display:none">hasCancerType::C00-C14: Mouth/throat cancers</span>
			<span style="display:none">hasCancerType::C15-C26: Digestive system cancers</span>
			<span style="display:none">hasCancerType::C30-C39: Lung/chest cancers</span>
			<span style="display:none">hasCancerType::C40-C41: Bone cancers</span>
			<span style="display:none">hasCancerType::C43-C44: Skin cancers/melanoma</span>
			<span style="display:none">hasCancerType::C45-C49: Soft tissue cancer</span>
			<span style="display:none">hasCancerType::C50: Breast cancer</span>
			<span style="display:none">hasCancerType::C51-C58: Female genitalia cancers</span>
			<span style="display:none">hasCancerType::C60-C63: Male genitalia cancer</span>
			<span style="display:none">hasCancerType::C64-C68: Urinary system cancers</span>
			<span style="display:none">hasCancerType::C69-C72: Eye and brain cancer</span>
			<span style="display:none">hasCancerType::C73-C75: Thyroid and other gland cancers</span>
			<span style="display:none">hasCancerType::C76-C80: Cancers of unknown or unspecified areas</span>
			<span style="display:none">hasCancerType::C81-C96: Cancers of the blood and immune system</span>
			<span style="display:none">hasCancerType::C97-C97: Cancers in multiple locations from the start</span>
			<span style="display:none">hasCancerType::D00-D09: Early-stage cancers not yet spread</span>
			<span style="display:none">hasCancerType::D10-D36: Benign tumour</span>
			<span style="display:none">hasCancerType::D37-D48: Growths of uncertain nature</span>
			<span style="display:none">hasCancerType::unknown</span>

Larysse at 14:46, 4 December 2025

2025-12-04T14:46:19Z

← Older revision		Revision as of 14:46, 4 December 2025
Line 2:		Line 2:
	<span style="display:none">forresearchers</span>		<span style="display:none">forresearchers</span>
	<span style="display:none">forproviders</span>		<span style="display:none">forproviders</span>
			<span style="display:none">latviacountry</span>
	Go back to [[Riga Eastern Clinical University Hospital]] page		Go back to [[Riga Eastern Clinical University Hospital]] page

Lucas: Update categories.

2025-12-02T14:00:50Z

Update categories.

← Older revision		Revision as of 14:00, 2 December 2025
Line 1:		Line 1:
	{{forpatients}}		<span style="display:none">forpatients</span>
	{{forresearchers}}		<span style="display:none">forresearchers</span>
	{{forproviders}}		<span style="display:none">forproviders</span>
	Go back to [[Riga Eastern Clinical University Hospital]] page		Go back to [[Riga Eastern Clinical University Hospital]] page

Francine: Created page with "{{forpatients}} {{forresearchers}} {{forproviders}} Go back to Riga Eastern Clinical University Hospital page '''NCTID''': NCT01903733 '''Title''': Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008 '''Study Summary''': The objective of the study is to provide long term access to bosutinib treatment and assess long term safety, tolerability and durat..."

2023-12-04T18:58:09Z

Created page with "{{forpatients}} {{forresearchers}} {{forproviders}} Go back to Riga Eastern Clinical University Hospital page '''NCTID''': NCT01903733 '''Title''': Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008 '''Study Summary''': The objective of the study is to provide long term access to bosutinib treatment and assess long term safety, tolerability and durat..."

New page

{{forpatients}}
{{forresearchers}}
{{forproviders}}
Go back to [[Riga Eastern Clinical University Hospital]] page

'''NCTID''': NCT01903733
'''Title''': Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008
'''Study Summary''': The objective of the study is to provide long term access to bosutinib treatment and assess long term safety, tolerability and duration of clinical benefit, without any formal hypothesis testing; therefore, there is no formal primary endpoint.
'''Sponsor''': Pfizer
'''Intervention''': bosutinib
'''Start Date''': 2013-08-28
'''Last Updated''': 2022-07-19
'''Number of Patients''': 281
'''Recruitment Status''': COMPLETED
'''Condition''': Chronic Myeloid Leukemia
'''NCTID''': NCT03425643
'''Title''': Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
'''Study Summary''': This trial will evaluate the safety and efficacy of pembrolizumab (MK-3475) in combination with platinum doublet neoadjuvant chemotherapy (NAC) before surgery <math display="block">neoadjuvant phase</math>, followed by pembrolizumab alone after surgery <math display="block">adjuvant phase</math> in participants with resectable stage II, IIIA, and resectable IIIB (T3-4N2) non-small cell lung cancer (NSCLC). The primary hypotheses of this study are that neoadjuvant pembrolizumab (vs. placebo) in combination with NAC, followed by surgery and adjuvant pembrolizumab (vs. placebo) will improve: 1) event free survival (EFS) by biopsy assessed by local pathologist or by investigator-assessed imaging using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1); and 2) overall survival (OS).
'''Sponsor''': Merck Sharp & Dohme LLC
'''Intervention''': Pembrolizumab
'''Start Date''': 2018-04-24
'''Last Updated''': 2023-11-13
'''Number of Patients''': 797
'''Recruitment Status''': ACTIVE_NOT_RECRUITING
'''Condition''': Non-small Cell Lung Cancer
'''NCTID''': NCT04464226
'''Title''': Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
'''Study Summary''': The aim of this study is to provide darolutamide treatment to patients who participated in a previous study with darolutamide supported by Bayer and the treating doctor considers that the continuation of the treatment with darolutamide to be beneficial. Patients will be carried over from the previous studies and continue in this study with darolutamide treatment on the same dosage. They will also return to the study centers for doctor’s visits as often as they did in the previous study.
'''Sponsor''': Bayer
'''Intervention''': Darolutamide (Nubeqa, BAY1841788)
'''Start Date''': 2020-10-20
'''Last Updated''': 2023-11-18
'''Number of Patients''': 678
'''Recruitment Status''': RECRUITING
'''Condition''': Cancer
'''NCTID''': NCT00910091
'''Title''': The Study of Oral Steroid Sulphatase Inhibitor BN83495 Versus Megestrol Acetate (MA) in Women With Advanced or Recurrent Endometrial Cancer
'''Study Summary''': This trial will explore the safety and efficacy of BN83485 compared to Megestrol Acetate (MA) on progression free survival (PFS) in post menopausal patients with endometrial cancer.
'''Sponsor''': Ipsen
'''Intervention''': BN83495
'''Start Date''': 2009-08
'''Last Updated''': 2019-01-30
'''Number of Patients''': 73
'''Recruitment Status''': COMPLETED
'''Condition''': Endometrial Cancer
'''NCTID''': NCT02425891
'''Title''': A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)
'''Study Summary''': This multicenter, randomized, double-blind study evaluated the efficacy, safety, and pharmacokinetics of atezolizumab (MPDL3280A) administered with nab-paclitaxel compared with placebo in combination with nab-paclitaxel in participants with locally advanced or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic breast cancer (mBC). The safety of single-agent nab-paclitaxel has been determined in previous studies of participants with mBC and the safety data to date suggest that atezolizumab can be safely combined with standard chemotherapy agents.
'''Sponsor''': Hoffmann-La Roche
'''Intervention''': Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody
'''Start Date''': 2015-06-23
'''Last Updated''': 2022-07-19
'''Number of Patients''': 902
'''Recruitment Status''': COMPLETED
'''Condition''': Triple Negative Breast Cancer
'''NCTID''': NCT05171049
'''Title''': A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE
'''Study Summary''': This is a Phase 3,multicenter, randomized, open-label, blinded endpoint evaluation study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE (ASTER)
'''Sponsor''': Anthos Therapeutics, Inc.
'''Intervention''': Abelacimab
'''Start Date''': 2022-05-05
'''Last Updated''': 2023-11-21
'''Number of Patients''': 1655
'''Recruitment Status''': RECRUITING
'''Condition''': Venous Thromboembolism
'''NCTID''': NCT01018953
'''Title''': Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome
'''Study Summary''': The purpose of the protocol is to assess the efficacy and safety of BIM 23A760 on patient’s overall satisfaction in terms of symptom relief (diarrhoea and/or flushes) in patients with carcinoid syndrome after 24 weeks of treatment.
'''Sponsor''': Ipsen
'''Intervention''': BIM 23A760
'''Start Date''': 2010-02
'''Last Updated''': 2020-11-20
'''Number of Patients''': 8
'''Recruitment Status''': TERMINATED
'''Condition''': Carcinoid Syndrome
'''NCTID''': NCT02106546
'''Title''': Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
'''Study Summary''': The purpose of this study is to evaluate the safety and efficacy of the addition of veliparib plus carboplatin and paclitaxel versus the addition of placebo plus carboplatin and paclitaxel in adults with advanced or metastatic squamous non-small cell lung cancer (NSCLC).
'''Sponsor''': AbbVie
'''Intervention''': Carboplatin
'''Start Date''': 2014-04-10
'''Last Updated''': 2020-11-17
'''Number of Patients''': 970
'''Recruitment Status''': COMPLETED
'''Condition''': Squamous Non-Small Cell Lung Cancer
'''NCTID''': NCT00545129
'''Title''': A Study Of Tanezumab as Add-On Therapy to Opioid Medication In Patients With Pain Due To Cancer That Has Spread To Bone
'''Study Summary''': The purpose of this study is to investigate the safety and efficacy of tanezumab in combination with opioids in treating pain due to cancer that has spread to bone.
'''Sponsor''': Pfizer
'''Intervention''': Tanezumab 10 mg IV
'''Start Date''': 2009-04-29
'''Last Updated''': 2021-06-18
'''Number of Patients''': 59
'''Recruitment Status''': COMPLETED
'''Condition''': Neoplasm Metastasis
'''NCTID''': NCT04961996
'''Title''': A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician’s Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
'''Study Summary''': This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with endocrine therapy of physician’s choice in participants with medium- and high-risk Stage I-III histologically confirmed estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative early breast cancer. In addition, an open-label exploratory substudy will explore the safety and efficacy of giredestrant in combination with abemaciclib in a subset of the primary study population.
'''Sponsor''': Hoffmann-La Roche
'''Intervention''': Giredestrant
'''Start Date''': 2021-08-27
'''Last Updated''': 2023-11-18
'''Number of Patients''': 4200
'''Recruitment Status''': RECRUITING
'''Condition''': Early Breast Cancer
'''NCTID''': NCT00440310
'''Title''': Phase 3 Trial of Litx™ Plus Chemotherapy vs. Chemotherapy Only Treating Colorectal Cancer Patients With Recurrent Liver Metastases
'''Study Summary''': The purpose of the study is to assess the overall survival and progression free survival of patients treated with Litx™ + chemotherapy versus chemotherapy alone in the treatment of Colorectal Cancer with recurrent liver metastases, and to demonstrate the safety of Litx™ therapy. Litx™ consists of a light-activated drug, talaporfin sodium (LS11, Light Sciences Oncology, Bellevue, Washington), and a light generating device, composed of light-emitting diodes (LEDs), that is energized by a power controller and percutaneously placed in the target tumor tissue inside the body.
'''Sponsor''': Light Sciences Oncology
'''Intervention''': Talaporfin sodium
'''Start Date''': 2007-02
'''Last Updated''': 2015-08-25
'''Number of Patients''': 483
'''Recruitment Status''': COMPLETED
'''Condition''': Liver Metastases
'''NCTID''': NCT00707304
'''Title''': Safety and Efficacy of Talactoferrin in Previously Treated Patients With Non-small Cell Lung Cancer
'''Study Summary''': The purpose of this study is to determine whether talactoferrin can improve overall survival in patients with non-small cell lung cancer (NSCLC) who have been previously treated with two or more regimens.
'''Sponsor''': Agennix
'''Intervention''': Talactoferrin
'''Start Date''': 2008-11
'''Last Updated''': 2012-08-21
'''Number of Patients''': 742
'''Recruitment Status''': COMPLETED
'''Condition''': Non Small Cell Lung Cancer
'''NCTID''': NCT00915018
'''Title''': Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer
'''Study Summary''': This study is investigating the effects of an experimental drug (neratinib) in combination with paclitaxel versus trastuzumab in combination with paclitaxel for the treatment of women who have not received previous treatment for erbB-2-positive locally recurrent or metastatic breast cancer. The study will compare the effectiveness of each regimen in shrinking tumors and extending the lives of women with erbB-2 (HER2) positive breast cancer. The study will also compare the safety of the two regimens and as well as the quality of life of subjects receiving either regimen.
'''Sponsor''': Puma Biotechnology, Inc.
'''Intervention''': Neratinib
'''Start Date''': 2009-08-21
'''Last Updated''': 2018-08-22
'''Number of Patients''': 479
'''Recruitment Status''': COMPLETED
'''Condition''': Breast Cancer
'''NCTID''': NCT02163694
'''Title''': A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer
'''Study Summary''': The primary objective of the study is to assess the progression-free survival (PFS) of veliparib in combination with carboplatin and paclitaxel (C/P) compared to placebo plus C/P in participants with a Breast Cancer Gene 1 or 2 (BRCA1; BRCA2) mutation in Human Epidermal Growth Factor Receptor 2 (HER2)-negative metastatic or locally advanced unresectable breast cancer. The secondary objectives of the study are to assess overall survival (OS), clinical benefit rate (CBR) through the end of Week 24, objective response rate (ORR) and PFS on subsequent therapy (PFS2) in participants treated with veliparib in combination with C/P versus placebo in combination with C/P.
'''Sponsor''': AbbVie
'''Intervention''': Veliparib Placebo
'''Start Date''': 2014-07-17
'''Last Updated''': 2023-02-16
'''Number of Patients''': 509
'''Recruitment Status''': ACTIVE_NOT_RECRUITING
'''Condition''': Metastatic Breast Cancer
'''NCTID''': NCT02657434
'''Title''': A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)
'''Study Summary''': This is a randomized, Phase III, multicenter, open-label study designed to evaluate the safety and efficacy of atezolizumab in combination with cisplatin or carboplatin + pemetrexed compared with treatment with cisplatin or carboplatin + pemetrexed in participants who are chemotherapy-naive and have Stage IV non-squamous NSCLC. Eligible participants will be randomized by a 1:1 ratio into 2 groups: Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed) and Arm B (Carboplatin or Cisplatin + Pemetrexed). The study will be conducted in two phases: Induction Phase and Maintenance Phase.
'''Sponsor''': Hoffmann-La Roche
'''Intervention''': Atezolizumab
'''Start Date''': 2016-04-30
'''Last Updated''': 2023-11-21
'''Number of Patients''': 578
'''Recruitment Status''': COMPLETED
'''Condition''': Non-Small Cell Lung Cancer
'''NCTID''': NCT00600340
'''Title''': 2-arm Trial of Paclitaxel Plus Bevacizumab vs. Capecitabine Plus Bevacizumab
'''Study Summary''': First-line treatment of patients with locally recurrent or metastatic, HER2-negative breast cancer who have not received prior chemotherapy for locally recurrent or metastatic disease.
'''Sponsor''': Central European Cooperative Oncology Group
'''Intervention''': Bevacizumab and Paclitaxel
'''Start Date''': 2008-04
'''Last Updated''': 2019-12-30
'''Number of Patients''': 564
'''Recruitment Status''': COMPLETED
'''Condition''': Metastatic Breast Cancer
'''NCTID''': NCT05353257
'''Title''': A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer
'''Study Summary''': This study is a randomized, double-blind, multicenter, phase III clinical study to compare the clinical efficacy and safety of Serplulimab + chemotherapy+ concurrent radiotherapy vs chemotherapy+ concurrent radiotherapy in subjects with Limited-Stage Small Cell Lung Cancer.
'''Sponsor''': Shanghai Henlius Biotech
'''Intervention''': Serplulimab
'''Start Date''': 2022-05-17
'''Last Updated''': 2023-10-10
'''Number of Patients''': 482
'''Recruitment Status''': RECRUITING
'''Condition''': Limited-Stage Small Cell Lung Cancer
'''NCTID''': NCT03033511
'''Title''': A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)
'''Study Summary''': This is a Phase 3, randomized, double-blind, placebo-controlled, multinational, and multicenter study to evaluate the efficacy of rovalpituzumab tesirine as maintenance therapy following first-line platinum-based chemotherapy.
'''Sponsor''': AbbVie
'''Intervention''': Placebo for dexamethasone
'''Start Date''': 2017-02-07
'''Last Updated''': 2021-07-29
'''Number of Patients''': 748
'''Recruitment Status''': TERMINATED
'''Condition''': Small Cell Lung Cancer

Trials (Riga Eastern Clinical University Hospital) - Revision history

Francine at 13:23, 15 December 2025

Lucas: Update categories.

Larysse at 14:46, 4 December 2025

Lucas: Update categories.